Join us for the 2018 New Investigators Forum! The New Investigator Forum will be held on Monday, July 16 from 6:30 – 8:30 pm. The focus of our program is to provide attendees with insights on career development and the future of the science. This year’s forum was developed by the ISSX New Investigator Group and it will be our third event. The program will again highlight opportunities in different sectors of the pharmaceutical sciences (Academia, Biotech, Government, and Industry) with an emphasis on making oneself more marketable to potential employers and acquiring leadership skills for a successful career.
The 2018 New Investigators Forum will be moderated by the New Investigator Group Chair, Jessica Hartman of Duke University, New Investigator Group Member, Ryan Takahashi of Genentech, and Council Member and ISSX Membership Affairs Committee Chair, Natalie Hosea of Takeda California. Forum Set-Up The forum will be organized as round table discussions with one senior and one junior representative from the four sectors leading each table (for a total of 8 tables).
Each of the invited representatives will lead a table and they will be divided into two table sets: Set A (tables 1-4) and Set B (tables 5-8). The two sets will each have representation from each sector with the junior and senior representatives split between table sets.
Attendees will receive a group assignment 1-8 when they arrive.
The attendees in groups 1-4 will rotate through tables 1-4 and attendees in groups 5-8 will rotate through tables 5-8.
Each group will spend 15 minutes at each of their set tables (for a total of one hour).
At the end of the assigned hour, attendees can choose their own table (one they previously visited or one from the other set).
A networking reception will be held during the last thirty minutes of the program.
Topics that will be addressed include: employers’ expectations at the time of hiring, and the necessary skill sets for career advancement and leadership development. This event will be of particular interest to graduate students, postdoctoral fellows, and investigators in the early stages of their careers.
Table Leaders The group identified key individuals in these sectors to be table leaders. View the table leaders and their biosketches below. When you register to attend the meeting, be sure to select this free event option in your registration! Academia Senior Investigator:
Kathy Giacomini, Department of Bioengineering and Therapeutic Sciences, UCSF Dr. Giacomini is a Professor in the Department of Bioengineering and Therapeutic Sciences at the University of California, San Francisco. She is currently Co-Principal Investigator of the NIH Pharmacogenomics Research Network Hub, and Co-Principal Investigator of the UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation (CERSI), a major center funded by the FDA with the goal of advancing scientific issues related to the safe and effective use of medical products. Dr. Giacomini is considered a leader in the field of membrane transporters, and in particular, she is widely recognized for her work on transporter genomics and pharmacogenomics. Kathy has been recognized by many awards and is an elected member of the National Academy of Medicine; a recipient of an honorary doctoral degree from Uppsala University; and in 2017, she was awarded the North American Scientific Achievement Award from the International Society for the Study of Xenobiotics.
Early Career Investigator:
Colin Ross, Faculty of Pharmaceutical Sciences, UBC Colin Ross is an Assistant Professor at the University of British Columbia and has provided this statement: I’m probably a good example of what not to do to get an academic position. After my PhD, I was a postdoc for a long, long, time. Then I received a soft academic position as an assistant professor that required me to obtain salary awards to keep my job, which was stressful. Eventually I found a solid academic position, where I am now as I an assistant professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia. My research aims to develop and deliver safer and more effective therapeutic options to patients based on the genetics of the individual patient. I love what I do, and if I didn’t love what I do that I would have chosen a different career path long ago. I’ve had the opportunity to be on several recruitment committees for new investigators and I can give you my perspective on what they seem to be looking for – but you probably know all that – so I’ll probably just mention a few things that have stood out to me.
Biotech Senior Investigator:
Margaret Bradbury, Nonclinical Development at Prana Biotechnology Dr. Bradbury is Vice President of Nonclinical Development at Prana Biotechnology, a biotechnology company in Australia developing drug candidates for neurodegenerative diseases. She received her Ph.D. in Neurosciences from the University of California, San Francisco and was a postdoctoral fellow at Stanford University and Salk Institute for Biology. Over the last 18 years, Margaret has served in roles of increasing responsibility at various biotechnology and pharmaceutical companies in pharmacology and nonclinical development. From 2008 through 2015, Margaret’s work at Auspex and then Teva Pharmaceuticals led to the approval of Austedo, the first approved deuterium-substituted small molecule drug for chronic therapy. Currently, Margaret oversees nonclinical research and development of early and clinical phase drug candidates at Prana.
Early Career Investigator:
Howard Burt, Simcyp/Certara Howard Burt is a Consultant and Scientific Advisor at Simcyp. He completed a PhD at The University of Manchester, UK in 2008 followed by a post-doctoral position in the same group. His research at this time focused on the in vitro to in vivo extrapolation of drug-drug interactions caused by mechanism-based enzyme inhibition under the supervision of Dr Aleksandra Galetin and Prof Brian Houston. He has worked in DMPK groups at Pfizer (Sandwich, UK) and Merck Serono (Geneva, Switzerland) prior to joining Simcyp in 2011. He is currently responsible for the providing PBPK modelling and simulation consultancy services in addition to contributing to the development of mechanistic PBPK models and IVIVE approaches within the Simcyp Simulator, particularly focused on drug metabolism and transport.
Government Senior Investigator:
Steve Ferguson, NEIHS Stephen Ferguson is a research scientist in the National Toxicology Program (NTP) at the National Institute of Environmental Health Sciences (NIEHS). His primary role is to lead efforts within the NTP to develop physiologically-relevant in vitro models, paired with high dimensional assays, to unravel the dynamics of cellular responses to chemical exposures and predict human outcomes. Currently, primary focus areas include development and application of ‘organotypic’ 2D and 3D in vitro liver models integrated with high throughput transcriptomics, morphological imaging, cell viability and metabolomics to quantitatively translate molecular interactions to humans. Prior to joining the NTP, Steve led the ADME/Tox R&D program of Life Technologies developing in vitro liver models and assay approaches for prediction of drug metabolism, transport, toxicity, and drug-drug interaction potential in humans.
Early Career Investigator:
Xinning Yang, FDA Dr. Xinning Yang is a Policy Lead in the Guidance & Policy team (GPT) under the Office of Clinical Pharmacology (OCP), Center for Drug Evaluation and Research (CDER) of the FDA. He obtained his Ph.D. in Pharmaceutical Science from the University at Buffalo, mentored by Dr. Marilyn Morris. In the past, he reviewed numerous IND/NDA submissions contributing to the benefit/risk assessment of neurology drug products. His current primary focus is guidance/policy development in DMPK and drug-drug interactions related Clinical Pharmacology issues. He is also active in research and leads or co-leads several research projects funded internally. He served as the Chair of the Transporter Scientific Interest Group (SIG) of OCP from 2014 to 2015. He has received several individual and team awards from CDER which recognized his excellent work and contribution to regulatory science and research. He published ten peer-reviewed articles and gave presentations or served as a moderator at multiple meetings.
Industry Senior Investigator:
David Stresser, DMPK-Translational Modeling, AbbVie David Stresser is a Principal Research Scientist in the DMPK-Translational Modeling department at AbbVie. Prior to joining AbbVie in 2016, he held research, management and business development positions at Gentest Corporation, BD Biosciences and Corning Life Sciences in Woburn, MA. He received post-doctoral training in the laboratory of David Kupfer at the University of Massachusetts Medical School in Worcester, Massachusetts and graduate work in the laboratories of David E. Williams and George S. Bailey at Oregon State University in Corvallis, OR, receiving a Ph.D. in toxicology in 1994. Dr. Stresser has authored or co-authored > 40 articles or book chapters in the field of drug metabolism and has been an invited speaker at various national and international meetings, pharmaceutical companies and universities.
Early Career Investigator:
Will Proctor, Investigative Toxicology, Genentech Will Proctor is an Associate Director/Senior Scientist and Head of Investigative Toxicology in the Department of Safety Assessment at Genentech. Prior to joining Genentech in 2013, Will earned his PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill in the laboratory of Dr. Dhiren Thakker with a focus on drug transport and pharmacokinetics. He then performed postdoctoral training at the National Institutes of Health in Bethesda, MD in the laboratory of Dr. Lance Pohl, focusing on immune mechanisms of drug-induced liver injury. At Genentech, Will serves as both a discovery toxicologist and group leader of the Investigative Toxicology group, whose focus is to support preclinical safety assessment through hypothesis-driven in vitro and ex vivo mechanistic studies. Will has continued his research interests in drug-induced liver injury at Genentech, where his focus has been on evaluating novel preclinical tools for assessing hepatotoxicity risk in drug discovery.
ISSX 2025 M Street NW Suite 800 Washington, DC 20036 USA